51672-1397 : Tavaborole 43.5 mg/ml Topical Solution


NDC: 51672-1397
Labeler: Taro Pharmaceuticals U.S.a., Inc.
Product Type: Human Prescription Drug
Drug Name:  Tavaborole
Dosage Form: Topical Solution
Application #: ANDA212215
Rev. Date: 


NDC Package Codes:

  • 51672-1397-9: 1 BOTTLE, WITH APPLICATOR IN 1 CARTON (51672‑1397‑9) > 10 ML IN 1 BOTTLE, WITH APPLICATOR

Active Ingredients:

  • Tavaborole

Dosage Strength:

  • 43.5 mg/mL

Pharmaceutical Classes:

  • Boron Compounds [CS]
  • Oxaborole Antifungal [EPC]
  • Protein Synthesis Inhibitors [MoA]

Related Products:

Based on records with the same trade name.
  • 0574-0157 Tavaborole 43.5 mg/ml Topical Solution by Paddock Laboratories, LLC.
  • 21922-020 Tavaborole 43.5 mg/ml Topical Solution by Encube Ethicals Private Limited
  • 51862-690 Tavaborole 43.5 mg/ml Topical Solution by Mayne Pharma Inc.
  • 62135-663 Tavaborole 43.5 mg/ml Topical Solution by Chartwell Rx, LLC
  • 62332-467 Tavaborole 43.5 mg/ml Topical Solution by Alembic Pharmaceuticals, Inc.
  • 63629-8704 Tavaborole 43.5 mg/ml Topical Solution by Bryant Ranch Prepack
  • 68180-958 Tavaborole 43.5 mg/ml Topical Solution by Lupin Pharmaceuticals, Inc.
  • 69097-686 Tavaborole 43.5 mg/ml Topical Solution by Cipla USA Inc.
  • 69238-1657 Tavaborole 43.5 mg/ml Topical Solution by Amneal Pharmaceuticals Ny LLC
  • 70771-1826 Tavaborole 43.5 mg/ml Topical Solution by Zydus Lifesciences Limited
  • 72578-102 Tavaborole 43.5 mg/ml Topical Solution by Viona Pharmaceuticals Inc

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 51672-1397 QR Code

< Prev: 51672-1396Next: 51672-1399 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.